0KCC Stock Chart & Stats
$4.81
-$0.07(-1.46%)
At close: 4:00 PM EDT
$4.81
-$0.07(-1.46%)
Day’s Range― - ―
52-Week Range$2.43 - $7.77
Previous CloseN/A
Volume350.00
Average Volume (3M)240.00
Market Cap
$141.37M
Enterprise Value$200.97
Total Cash (Recent Filing)$17.76M
Total Debt (Recent Filing)$2.63M
Price to Earnings (P/E)―
Beta0.41
Next Earnings
Nov 05, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.52
Shares Outstanding32,724,285
10 Day Avg. Volume693
30 Day Avg. Volume240
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)-7.26
Price to Sales (P/S)56.37
P/FCF Ratio-9.01
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$10.50Price Target Upside118.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.88
Revenue Forecast (FY)$1.61M
Bulls Say, Bears Say
Bulls Say
Progress Toward FDA AuthorizationSustained regulatory progress toward FDA authorization is a durable operational inflection: a kitted approval converts the company from an R&D/regulatory-stage lab into a commercial supplier, materially increasing addressable customers and enabling scale of kit sales and reimbursement capture over multiple years, reducing long-run reliance on small RUO and lab-service revenues.
Expanded Medicare Reimbursement (MolDX)A structural expansion in Medicare surveillance frequency meaningfully increases the tested TAM and per-patient utilization, improving the economic case for in-house kitted testing. Enduring reimbursement policy shifts support sustained demand and provide a repeatable revenue stream per transplant patient, improving long-term commercial viability once product is authorized.
Strong Clinical Data And Customer EngagementRobust peer-reviewed performance and substantial engagement from leading transplant centers create durable adoption advantages: clinical superiority and influential early adopters lower commercial friction, accelerate guideline and payer acceptance, and form a competitive moat that supports broader lab and hospital partnerships over multiple years.
Bears Say
Negative Stockholders' EquityCumulative losses that produced negative equity indicate weakened balance‑sheet flexibility and heightened refinancing risk. This structural erosion limits borrowing capacity, increases the probability of dilutive equity raises, and constrains strategic optionality for M&A or investment over the next several quarters unless profitability or funding improves materially.
High Cash Burn And Weak Cash GenerationSustained multi‑million dollar quarterly cash burn relative to very low revenue is a persistent financing vulnerability. Continued negative operating and free cash flow creates dependency on external capital, risking dilution or disrupted execution if markets tighten; this structural funding need can impede long‑term commercialization pacing and strategic investments.
Modest Revenue Base And Low MarginsVery low revenue and weak gross margins show the business has not reached operating scale; the cost structure outpaces current sales, limiting internal cash generation and delaying operating leverage. Without significant volume growth from kit commercialization and reimbursement realization, path to sustainable profitability remains long and execution‑sensitive.
Insight Molecular Diagnostics News
0KCC FAQ
What was Insight Molecular Diagnostics’s price range in the past 12 months?
Insight Molecular Diagnostics lowest share price was $2.42 and its highest was $7.77 in the past 12 months.
What is Insight Molecular Diagnostics’s market cap?
Insight Molecular Diagnostics’s market cap is $141.37M.
When is Insight Molecular Diagnostics’s upcoming earnings report date?
Insight Molecular Diagnostics’s upcoming earnings report date is Nov 05, 2026 which is in 78 days.
How were Insight Molecular Diagnostics’s earnings last quarter?
Insight Molecular Diagnostics released its earnings results on Aug 10, 2026. The company reported -$0.31 earnings per share for the quarter, missing the consensus estimate of -$0.254 by -$0.056.
Is Insight Molecular Diagnostics overvalued?
According to Wall Street analysts Insight Molecular Diagnostics’s price is currently Undervalued.
Does Insight Molecular Diagnostics pay dividends?
Insight Molecular Diagnostics pays a Notavailable dividend of $0.285 which represents an annual dividend yield of N/A. See more information on Insight Molecular Diagnostics dividends here
What is Insight Molecular Diagnostics’s EPS estimate?
Insight Molecular Diagnostics’s EPS estimate is -0.23.
How many shares outstanding does Insight Molecular Diagnostics have?
Insight Molecular Diagnostics has 32,724,285 shares outstanding.
What happened to Insight Molecular Diagnostics’s price movement after its last earnings report?
Insight Molecular Diagnostics reported an EPS of -$0.31 in its last earnings report, missing expectations of -$0.254. Following the earnings report the stock price went down -9.917%.
Which hedge fund is a major shareholder of Insight Molecular Diagnostics?
Currently, no hedge funds are holding shares in GB:0KCC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Insight Molecular Diagnostics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.50 (118.30% Upside)
$10.50 (118.30% Upside)
Blogger Sentiment
Bearish
GB:0KCC Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
112.50%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-41.72%
Trailing 12-Months
Company Description
Insight Molecular Diagnostics
OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression analysis. Additionally, OncoCyte provides a range of expert services, such as biomarker discovery, assay design and refinement, and clinical trial assistance, which encompass offering various biomarker tests to pharmaceutical partners. A strategic partnership with Life Technologies Corporation focuses on the collaborative development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, intended for integration with the Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was founded in 2009 and maintains its principal office in Irvine, California.
0KCC Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveys a generally positive operational and commercial outlook driven by regulatory progress (SIR meeting and tripled study samples), favorable Medicare coverage expansion (+75% surveillance tests in first 3 years), strong head-to-head clinical data and customer engagement (over half of top-10 transplant centers engaged), and a clear TAM expansion pathway. Offsetting these positives are material near-term financial risks — elevated cash burn ($10M in Q2; expected ~$8M/quarter in H2, up ~33% vs prior guidance), ongoing adjusted EBITDA losses ($7.8M) and schedule uncertainty around FDA authorization that could delay commercialization. Overall, management’s tone is constructive and forward-looking, but execution and timing risks remain important near-term considerations.View all GB:0KCC earnings summaries0KCC Stock 12 Month Forecast
Average Price Target
$10.50
▲(118.30% Upside)
Technical Analysis
Atossa Therapeutics
―
MacroGenics
―
Elutia
―
Surrozen
―
Telomir Pharmaceuticals, Inc.
―